CHILI returns on November 13, 2020

After the huge success of the first two editions, CHILI – the Conference on Hybrid Imaging Live – returns with its engaging online-only conference format. On November 13, from 08:55-17:50 (CET), four sessions each consisting of 3 lectures and clinical case reviews will be broadcast virtually to the world. At the end of each session, there will be time for the audience to engage with the experts from the respective sessions and ask questions via an online tool.

Guiding clinical therapy with hybrid imaging
The four sessions of CHILI will cover various aspects relating to the fusion of radiology and nuclear medicine. The first three sessions are dedicated to exploring ways to guide clinical therapy with the use of hybrid imaging. Each of the lectures will be illustrated practically by a case review.

The focus of the first session will be on guiding clinical therapy in oncology, focussing on breast cancer, prostate cancer and immunotherapy. Subsequently, the second session will explore the possibilities on how hybrid imaging can help to guide clinical therapy in the heart, the brain and in children. After a short break and a session by our industry partner, the third session will present means how to guide clinical therapy in inflammation and infection, also beyond the use of FDG.

The conference will conclude with a session dedicated to new developments that are on the horizon for hybrid imaging, such as the great leap for full body PET/CT, novel tracers and a lecture on how to evolve clinical applications for artificial intelligence in hybrid imaging.

An accreditation request to UEMS has been made.


  • to learn the principles of guiding clinical therapy with hybrid medical imaging
  • to learn the key clinical questions at different points in the patient’s journey
  • to understand the indications, limitations and comparative merits of each part in hybrid medical imaging in a wide range of oncologic and non-oncologic conditions, including prostate cancer, breast cancer, cardiac diseases, neurodegeneration as well as inflammation and infection.
  • to appreciate the complementary roles of structural and functional/molecular imaging in cancer management
  • to understand how information derived from imaging guides patient selection for treatment and supports individualised treatment planning
  • to learn about new horizons for hybrid imaging, such as full body PET/CT, novel tracers and artificial intelligence in hybrid imaging